Skye Bioscience (SKYE) Corporate presentation summary

Strategic positioning and market opportunity

• Nimacimab is positioned as a complementary, scalable add-on to GLP-1 therapies, targeting patients who plateau, are intolerant, or need deeper weight loss beyond current standards.

• The expiration of semaglutide patents in major markets from 2026 creates a commercial opportunity for affordable combination therapies.

• Significant unmet need exists for GLP-1 experienced patients, as many do not achieve sufficient weight loss or discontinue therapy.

• Nimacimab combined with generic semaglutide could offer a cost-effective alternative, especially in markets with high obesity prevalence.

Clinical efficacy and safety data

• Combination of nimacimab and semaglutide achieved 22.3% mean weight loss at 52 weeks, with no plateau observed.

• The combination showed a 3.0% incremental weight loss over semaglutide alone at 26 weeks and improved body composition.

• No neuropsychiatric adverse events were observed with nimacimab, and the safety profile was similar to semaglutide alone.

• Durable weight loss was maintained during a 13-week off-treatment period, with minimal rebound compared to GLP-1 monotherapy.

Mechanism of action and differentiation

• Nimacimab is a peripherally-restricted CB1-inhibiting antibody, minimizing brain exposure and neuropsychiatric risk.

• Functions as both an antagonist and inverse agonist, binding allosterically and non-competitively to CB1.

• Demonstrates similar potency to small molecule CB1 inhibitors but with significantly less brain penetration.

• Modulates appetite-regulating hormones, improves glycemic control, enhances lipid metabolism, and reduces obesity-induced inflammation.